GH therapy is approved in the US for individuals aged ≥2 years with PWS and documented growth failure and can normalize height outcomes by 18 years of age (Table 3 and Figures 7A, B) (36, 108, 109). The gene discussed is GH1; the disease is Prader-Willi syndrome.